Author

David Laharie

Mistakes in acute severe ulcerative colitis and how to avoid them
Mistakes in acute severe ulcerative colitis and how to avoid them

David Laharie

What I regretted most in treatment of acute severe ulcerative colitis
What I regretted most in treatment of acute severe ulcerative colitis

David Laharie

CORTICOSTEROID-SPARING EFFECT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB MAINTENANCE THERAPY
CORTICOSTEROID-SPARING EFFECT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB MAINTENANCE THERAPY

David Laharie  et al.

PROLONGED BENEFIT OF FILGOTINIB IN PATIENTS WITH ULCERATIVE COLITIS IN SELECTION
PROLONGED BENEFIT OF FILGOTINIB IN PATIENTS WITH ULCERATIVE COLITIS IN SELECTION

David Laharie  et al.

WHICH SECOND-LINE BIOLOGIC AFTER ANTI-TNF FAILURE DURING CROHN'S DISEASE: USTEKINUMAB OR VEDOLIZUMAB, A MULTICENTRE RETROSPECTIVE STUDY
WHICH SECOND-LINE BIOLOGIC AFTER ANTI-TNF FAILURE DURING CROHN'S DISEASE: USTEKINUMAB OR VEDOLIZUMAB, A MULTICENTRE RETROSPECTIVE STUDY

David Laharie  et al.

CHANGING THE COURSE OF CROHN’S DISEASE WITH AN EARLY USE OF ADALIMUMAB: THE CURE STUDY FROM THE GETAID
CHANGING THE COURSE OF CROHN’S DISEASE WITH AN EARLY USE OF ADALIMUMAB: THE CURE STUDY FROM THE GETAID

David Laharie  et al.

IGA VASCULITIS ASSOCIATED WITH INFLAMMATORY BOWEL DISEASES: A MULTICENTER STUDY OF THE GETAID AND GFEV
IGA VASCULITIS ASSOCIATED WITH INFLAMMATORY BOWEL DISEASES: A MULTICENTER STUDY OF THE GETAID AND GFEV

David Laharie  et al.

LONG-TERM RISK OF DELAYED POSTOPERATIVE CROHN’S DISEASE RECURRENCE IN PATIENTS WITH NO OR MILD RECURRENCE AT FIRST ENDOSCOPIC ASSESSMENT
LONG-TERM RISK OF DELAYED POSTOPERATIVE CROHN’S DISEASE RECURRENCE IN PATIENTS WITH NO OR MILD RECURRENCE AT FIRST ENDOSCOPIC ASSESSMENT

David Laharie  et al.

USTEKINUMAB IS MORE EFFECTIVE THAN AZATHIOPRINE TO PREVENT ENDOSCOPIC POSTOPERATIVE RECURRENCE IN CROHN´S DISEASE
USTEKINUMAB IS MORE EFFECTIVE THAN AZATHIOPRINE TO PREVENT ENDOSCOPIC POSTOPERATIVE RECURRENCE IN CROHN´S DISEASE

David Laharie  et al.

ETROLIZUMAB AS INDUCTION AND MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM THE PHASE 3 BERGAMOT STUDY
ETROLIZUMAB AS INDUCTION AND MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM THE PHASE 3 BERGAMOT STUDY

David Laharie  et al.

INFLIXIMAB PLUS AZATHIOPRINE AND QUICK STEROIDS DISCONTINUATION VERSUS AZATHIOPRINE PLUS STEROIDS IN PATIENTS WITH ACUTE SEVERE ULCERATIVE COLITIS RESPONDING TO INTRAVENOUS STEROIDS: A PARALLEL, OPEN-LABEL RANDOMIZED CONTROLLED TRIAL
INFLIXIMAB PLUS AZATHIOPRINE AND QUICK STEROIDS DISCONTINUATION VERSUS AZATHIOPRINE PLUS STEROIDS IN PATIENTS WITH ACUTE SEVERE ULCERATIVE COLITIS RESPONDING TO INTRAVENOUS STEROIDS: A PARALLEL, OPEN-LABEL RANDOMIZED CONTROLLED TRIAL

David Laharie  et al.

IMPACT OF BIOLOGICS ON THE RISK OF EARLY POSTOPERATIVE COMPLICATIONS IN CROHN'S DISEASE: A FRENCH NATIONWIDE STUDY
IMPACT OF BIOLOGICS ON THE RISK OF EARLY POSTOPERATIVE COMPLICATIONS IN CROHN'S DISEASE: A FRENCH NATIONWIDE STUDY

David Laharie  et al.

COMPARISON OF THE RISK OF CROHN'S DISEASE POSTOPERATIVE RECURRENCE BETWEEN MODIFIED RUTGEERTS SCORE I2A AND I2B CATEGORIES: AN INDIVIDUAL PATIENT DATA META-ANALYSIS
COMPARISON OF THE RISK OF CROHN'S DISEASE POSTOPERATIVE RECURRENCE BETWEEN MODIFIED RUTGEERTS SCORE I2A AND I2B CATEGORIES: AN INDIVIDUAL PATIENT DATA META-ANALYSIS

David Laharie  et al.

EFFECTIVENESS AND SAFETY OF RISANKIZUMAB INDUCTION THERAPY IN PATIENTS WITH CROHN’S DISEASE: A GETAID COHORT STUDY
EFFECTIVENESS AND SAFETY OF RISANKIZUMAB INDUCTION THERAPY IN PATIENTS WITH CROHN’S DISEASE: A GETAID COHORT STUDY

David Laharie  et al.

EARLY FECAL CALPROTECTIN LEVELS PREDICT POSTOPERATIVE RECURRENCE OF CROHN’S DISEASE: DATA FROM THE REPREVIO TRIAL
EARLY FECAL CALPROTECTIN LEVELS PREDICT POSTOPERATIVE RECURRENCE OF CROHN’S DISEASE: DATA FROM THE REPREVIO TRIAL

David Laharie  et al.

ENDOSCOPIC SUBMUCOSAL DISSECTION IN INFLAMMATORY BOWEL DISEASE PATIENTS FOR VISIBLE DYSPLASIA: A FRENCH RETROSPECTIVE MULTICENTRIC STUDY
ENDOSCOPIC SUBMUCOSAL DISSECTION IN INFLAMMATORY BOWEL DISEASE PATIENTS FOR VISIBLE DYSPLASIA: A FRENCH RETROSPECTIVE MULTICENTRIC STUDY

David Laharie  et al.

CANCER INCIDENCE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND A PRIOR NON-DIGESTIVE MALIGNANCY ACCORDING TO THE IMMUNOMODULATORY THERAPY: A MULTICENTER COHORT STUDY
CANCER INCIDENCE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND A PRIOR NON-DIGESTIVE MALIGNANCY ACCORDING TO THE IMMUNOMODULATORY THERAPY: A MULTICENTER COHORT STUDY

David Laharie  et al.

IMPACT OF ABDOMINOPELVIC RADIOTHERAPY ON INFLAMMATORY BOWEL DISEASE ACTIVITY: A MULTICENTER COHORT STUDY FROM THE GETAID
IMPACT OF ABDOMINOPELVIC RADIOTHERAPY ON INFLAMMATORY BOWEL DISEASE ACTIVITY: A MULTICENTER COHORT STUDY FROM THE GETAID

David Laharie  et al.

Item 1 - 18 / 18
1